Drugs that contain Sevelamer Carbonate
1. Renvela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459151 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6509013 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6858203 | SANOFI | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | SANOFI | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | SANOFI | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US7985418 | SANOFI | Aliphatic amine polymer salts for tableting |
Oct, 2025
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
Market Authorisation Date: 19 October, 2007
Treatment: Phosphate binding
Dosage: TABLET;ORAL
How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage
RENVELA family patents
2. Renvela patents expiration
RENVELA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6509013 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6858203 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | GENZYME | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US9095509 | GENZYME | Sachet formulation for amine polymers |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 25, 2019 |
| New Dosage Form(NDF) | Aug 12, 2012 |
Market Authorisation Date: 18 February, 2009
Treatment: Phosphate binding
Dosage: FOR SUSPENSION;ORAL
How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage
RENVELA family patents